EXPLORE THE SCIENCE
TL;DR: A 2026 real-world study in Journal of Clinical Sleep Medicine found that glucagon-like peptide-1 receptor agonist use was associated with lower 3-year cardiovascular-event risk in adults with obesity and obstructive sleep apnea. Key Findings 18,523 matc…
Read article
TL;DR: A 2026 systematic review and meta-analysis in International Journal of Obesity found that glucagon-like peptide-1 receptor agonists, metabolic drugs that extend a satiety and glucose-control hormone pathway, reduced body weight mainly through fat loss w…
Read article
TL;DR: A 2026 review in Drug Design, Development and Therapy argued that glucagon-like peptide-1 (GLP-1) receptor agonists, drugs that mimic a metabolic hormone involved in glucose control, have credible brain-protection mechanisms, but clinical evidence for n…
Read article
TL;DR: A 2026 narrative review in Journal of Central Nervous System Disease found that glucagon-like peptide-1 receptor agonists have promising stroke-prevention and animal-model evidence, but human data do not yet support routine use as an acute ischemic stro…
Read article
TL;DR: A 2026 study in Stigma and Health found that women who lost 15% of body weight with GLP-1 receptor agonists, medications such as semaglutide that mimic a metabolic hormone involved in appetite and glucose signaling, were judged more harshly than women w…
Read article
TL;DR: A 2026 real-world cohort study in Journal of Diabetes & Metabolic Disorders linked GLP-1 receptor agonists, drugs targeting a glucose-related metabolic hormone pathway, to a higher hazard of new hypersomnolence, but the absolute risk increase was small.…
Read article
TL;DR: A 2026 meta-analysis in Sleep and Breathing found that GLP-1 drugs, metabolic hormone medications involved in glucose, appetite, and weight regulation, were linked to fewer obstructive sleep apnea breathing events in adults with obesity. Key Findings Sl…
Read article
TL;DR: A 2026 mouse study in Nature found that small-molecule glucagon-like peptide 1 receptor agonists (GLP-1RAs), obesity and diabetes drugs built around a glucose-linked hormone pathway, suppressed palatable-food intake through central amygdala neurons that…
Read article
TL;DR: A 2026 systematic review and exploratory network meta-analysis of 5 randomized trials in Neurological Sciences found dose-specific ON-medication motor improvements, measured while usual Parkinson’s drugs were active, for some GLP-1 receptor agonists, gl…
Read article